These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7882100)

  • 1. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine.
    Yerly S; Kaiser L; Baumberger C; Hirschel B; Perrin LH
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr; 8(4):358-64. PubMed ID: 7882100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of methods for coordinate measurement of total cell-associated and integrated human immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical samples: levels are not associated with clinical parameters, but low levels of integrated HIV-1 DNA may be prognostic for continued successful therapy.
    Carr JM; Cheney KM; Coolen C; Davis A; Shaw D; Ferguson W; Chang G; Higgins G; Burrell C; Li P
    J Clin Microbiol; 2007 Apr; 45(4):1288-97. PubMed ID: 17314225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [HIV-1 proviral DNA sequences in the saliva of patients with HIV infection].
    Piazza M; Chirianni A; Liuzzi G; Tullio Cataldo P; Santoro G; Barsanti L; Batoni G; Ceccherini Nelli L
    Boll Soc Ital Biol Sper; 1992 Jul; 68(7):475-81. PubMed ID: 1362355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
    Molina JM; Chêne G; Ferchal F; Journot V; Pellegrin I; Sombardier MN; Rancinan C; Cotte L; Madelaine I; Debord T; Decazes JM
    J Infect Dis; 1999 Aug; 180(2):351-8. PubMed ID: 10395849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biological assessment methods and understanding the course of the HIV infection.
    Katzenstein TL
    APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring viral load in the clinical setting.
    Harrigan R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S34-40. PubMed ID: 8595506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine].
    Gómez-Cano M; Soriano V; García-Lerma G; González-Lahoz J
    An Med Interna; 1998 Mar; 15(3):145-7. PubMed ID: 9567422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R; Jørgensen LB; Møller BK; Black FT; Kjems J; Obel N
    J Clin Virol; 2005 Dec; 34(4):257-67. PubMed ID: 16286049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 DNA and RNA kinetics in primary HIV infection.
    Lillo F; Grasso M; Lodini S; Capiluppi B; Lazzarin A; Tambussi G
    J Biol Regul Homeost Agents; 2002; 16(1):49-52. PubMed ID: 12003174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Viraemia and p24 antigenaemia are independent risk factors for the emergency of a zidovudine-resistant genotype in nucleoside analogue-treated HIV-1 infection.
    Relimpio F; Rey C; Pineda JA; Leal M; Caruz A; Sánchez-Quijano A; Lissen E
    Antivir Ther; 1997 Apr; 2(2):99-104. PubMed ID: 11322281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study.
    Ruffault A; Michelet C; Jacquelinet C; Guist'hau O; Genetet N; Bariou C; Colimon R; Cartier F
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Jul; 9(3):243-8. PubMed ID: 7788423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The quantification of human immunodeficiency virus viremia in patients with rapid and slow progression of the disease].
    Bravo R; Soriano V; Martín R; del Romero J; Dronda F; Gutiérrez M; Martínez P; Valencia E; Moreno V; Laguna F
    Med Clin (Barc); 1995 Apr; 104(14):530-4. PubMed ID: 7776732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
    J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.
    Naugler WE; Yong FH; Carey VJ; Dragavon JA; Coombs RW; Frenkel LM
    J Infect Dis; 2002 Feb; 185(4):448-55. PubMed ID: 11865396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.